Top Industry Leaders in the Blepharitis Market
August 2023, the US Food and Drug Administration (FDA) approved Xdemvy (demeclocycline ophthalmic ointment) for the treatment of Demodex blepharitis. This is the first-ever FDA approved drug for this specific type of blepharitis, which is caused by microscopic mites called Demodex.
Xdemvy is expected to be a significant market driver, as it offers a new and effective treatment option for Demodex blepharitis patients.
January 2023, Bausch + Lomb acquired AcuFocus, a company developing innovative ophthalmic technologies. This acquisition gives Bausch + Lomb access to AcuFocus's pipeline of blepharitis treatments, including the IClarify™ excimer laser system for treating dry eye disease, which can be associated with blepharitis. This acquisition is expected to strengthen Bausch + Lomb's position in the blepharitis market and allow them to offer a wider range of treatment options.
List of Blepharitis Key companies in the market- Scope Ophthalmics Ltd
- Novartis AG
- InSite Vision Incorporated
- Thea Pharmaceuticals Limited
- Galderma S.A.
- NovaBay Pharmaceuticals, Inc.
- Merck & Co.
- Perrigo Laboratories
